As we roll into 2025, it’s an opportune time as ever to review an organization’s controlled substance inventory. Doing so ensures compliance and supports efficiency and safety in drug handling. It also provides the chance to ensure adherence to the Drug Enforcement Administration’s (DEA) controlled substance inventory biennial review and reporting requirements.
